

# HORIZON BIOTECHNOLOGY FUND

## At a glance

### Performance\*

The Fund returned 13.33%, the Index returned 10.75% and the Sector returned 12.57%.

### Contributors/detractors

Cytokinetics and ImmunoGen were among the top positive performers. Conversely, Akero Therapeutics and Sarpeta Therapeutics detracted from relative performance.

### Outlook

With the rate-hike cycle ending in the US, and innovation and merger and acquisition (M&A) activity accelerating, we believe biotech could be poised for a rebound.

## Portfolio management



Andy Acker, CFA



Daniel Lyons, Ph.D., CFA



Agustin Mohedas, Ph.D.

## Investment environment

- Biotechnology stocks rallied sharply towards the end of the year, outperforming the broader health care sector as the US Federal Reserve (Fed) signalled that its monetary tightening cycle may soon be over.
- A flurry of merger and acquisition (M&A) activity also buoyed the sector.
- In keeping with the risk-on backdrop, small- and mid-cap biotech stocks outperformed larger peers.

## Portfolio review

Looking at individual holdings, Cytokinetics was the top positive contributor. The firm's lead drug candidate, aficamten, is a small molecule myosin inhibitor being studied for hypertrophic cardiomyopathy (HCM), a condition that causes a thickening of the heart muscle and restricts blood flow. Its share price soared after Cytokinetics reported positive phase 3 results for aficamten, which showed a statistically significant and clinically meaningful improvement in exercise capacity in patients. Big pharma has demonstrated interest in novel targeted therapies for cardiovascular disease (such as Bristol-Myer Squibb's \$13 billion acquisition of a rival drug in 2020), which has prompted market participants to speculate that Cytokinetics could be an acquisition candidate.

ImmunoGen also aided performance. The company's share price surged when AbbVie announced plans to buy it for \$10 billion, representing a 95% premium to the prior closing price. (Janus Henderson was among the top active holders.) ImmunoGen develops antibody drug conjugates (ADC), among the hottest areas of cancer research. One can think of an ADC as a precision-guided missile that brings chemotherapy directly to cancer cells with less collateral toxicity. Earlier this year, ovarian cancer patients taking ImmunoGen's Elahere saw a 33% reduction in mortality risk compared to chemotherapy - the first time an overall survival benefit had been achieved in chemo-resistant ovarian cancer. AbbVie said it expects to complete the acquisition by mid-2024.

### Marketing communication

For qualified investors only.

Past performance does not predict future returns.

\*For benchmark and sector, if applicable, refer to Fund details on page 3. For relevant descriptions, risks and the Fund's investment policy statement, refer to Additional fund information on page 4.

Conversely, Akero Therapeutics weighed on performance. The biotech firm is developing efruxifermin for non-alcoholic steatohepatitis (NASH), a fatty liver disease that affects over 10 million adults in the US and is a leading cause of liver failure. The company reported phase 2 data in the most severe NASH patients and failed to hit statistical significance on the main endpoint, in this case for fibrosis reversal. Despite achieving statistical significance on other disease markers and prior trials that prove the drug's benefit in moderate NASH patients, investors beat a retreat. We believe this had a lot to do with the recent perception that GLP-1 receptor agonists will crowd out the rest of the NASH market, which is misguided, in our view.

Sarepta Therapeutics was another detractor. We have been long-term holders of the company, a leader in the field of Duchenne muscular dystrophy with a marketed exon-skipping franchise approaching \$1 billion in sales and a novel gene therapy, Elevidys, that could be game-changing for patients. The process of bringing Elevidys to market has had its ups and downs. In June, the US Food and Drug Administration (FDA) granted accelerated approval for four and five year olds, pending a confirmatory trial. In October, that trial missed on its primary endpoint, although it did show benefit on multiple key secondary endpoints. As such, the FDA could permit Elevidys to stay on the market and even allow a broader indication given the clinical benefits observed and high unmet medical need.

## Manager outlook

Following a sharp sell-off, biotechnology stocks rebounded in the final months of 2023, benefiting from optimism the

rate-tightening cycle in the US was coming to an end. Positive clinical data and a surge of M&A activity also boosted investor sentiment, which in our view could continue to propel biotechnology stocks in the new year.

We believe the low valuations (at the time of writing) are attractive. As Treasury yields climbed in 2023, markets punished biotech firms that failed to meet clinical milestones or fell short in other ways. While some industry rationalisation was arguably needed - the sector saw a surge of new biotech companies funded during the pandemic, many without proof-of-concept data - we feel many valuations were pushed too low.

At the same time, innovation has been accelerating, with the FDA approving a record 73 new therapies in 2023. Many of these drugs target large disease categories (such as obesity, autoimmune disease, cancer and Alzheimer's), that could represent major new product cycles and drive revenue growth for the next decade. We expect no shortage of additional data readouts and approvals in 2024.

M&A activity has also picked up in recent months and could maintain momentum as biopharma firms, typically flush with cash, seeks to replace blockbuster products losing patent protection in the coming years. Growing market opportunities, including GLP-1s (for diabetes and obesity), gene editing, antibody drug conjugates, radiopharma and cell therapy treatments for autoimmune diseases, could also tempt biopharma companies to break out their checkbooks. In short, we believe the set-up for biotech is compelling heading into 2024. We feel that M&A, innovation and attractive valuations combine to offer a good investment opportunity over the year ahead.

Performance (%)

Returns	Cumulative				Annualised			
	1 Month	3 Month	YTD	1 Year	3 Year	5 Year	10 Year	Since inception (10/12/18)
A2 USD (Net)	15.59	13.33	23.28	23.28	4.00	19.58	—	17.51
Index	12.91	10.75	4.59	4.59	-2.03	8.26	—	6.66
Sector	13.44	12.57	5.26	5.26	-6.98	5.17	—	3.61
A2 USD (Gross)	—	—	—	—	—	23.39	—	21.23
Target	—	—	—	—	—	10.43	—	8.79

Calendar year	2023	2022	2021	2020	2019	2018 from 10 Dec
A2 USD (Net)	23.28	-3.78	-5.17	61.32	34.70	-7.50
Index	4.59	-10.12	0.02	26.42	25.11	-6.85
Sector	5.26	-17.17	-7.68	27.50	25.36	-7.02

Performance is on a net of fees basis, with gross income reinvested. Source: at 31/12/23. © 2024 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. **Past performance does not predict future returns.** Performance/performance target related data will display only where relevant to the share class inception date and annualised target time period. **The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.** Source for target returns (where applicable) - Janus Henderson Investors.

Fund charges will impact the value of your investment. In particular, the ongoing charges applicable to each fund will dilute investment performance, particularly over time. For further explanation of charges please visit our Fund Charges page at [www.janushenderson.com](http://www.janushenderson.com).

Performance fees may be charged before the Fund's outperformance target is reached. Performance fees are charged separately as a way of rewarding the investment manager for superior returns or for outperforming specified targets. A Performance Fee is accrued where the NAV outperforms the relevant Hurdle NAV (subject to a High Water Mark). For further explanation of the performance fee calculation methodology please see the relevant prospectus, available at [www.janushenderson.com](http://www.janushenderson.com).

Investment objective

The Fund aims to provide capital growth over the long term. Performance target: To outperform the NASDAQ Biotechnology Total Return Index by 2% per annum, before the deduction of charges, over any 5 year period.

For the fund's investment policy, refer to the Additional fund information on page 4. **Past performance does not predict future returns.**

Fund details

Inception date	10 December 2018
Total net assets	195.93m
Asset class	Equities
Domicile	Luxembourg
Structure	SICAV
Base currency	USD
Index	NASDAQ Biotechnology Total Return Index
Morningstar sector	Sector Equity Biotechnology

## Additional fund information

Tax assumptions and reliefs depend upon an investor's particular circumstances and may be subject to change. Please note the performance target is to be achieved over a specific annualised time period. Refer to the performance target wording within the objective. With effect from 1 January 2023, the Key Investor Information document (KIID) changed to the Key Information Document (KID), except in the UK where investors should continue to refer to the KIID. Availability of share classes shown may be limited by law in certain jurisdictions. Performance records/scenarios are detailed within the fund's specific KIID/KID; fees and charges, and the respective risk rating may vary. Further information can be found in the fund's prospectus and KIID/KID, which must be reviewed before investing. Please consult your local sales representative and/or financial adviser if you have any queries. From 31 January 2023 Agustín Mohedas also manages this fund. Note that any differences among portfolio securities currencies, share class currencies and costs to be paid or represented in currencies other than your home currency will expose you to currency risk. Costs and returns may increase or decrease as a result of currency and exchange rate fluctuations. Investment into the fund will acquire units/shares of the fund itself and not the underlying assets owned by the fund. References made to individual securities do not constitute a recommendation to buy, sell or hold any security, investment strategy or market sector, and should not be assumed to be profitable. Janus Henderson Investors, its affiliated advisor, or its employees, may have a position in the securities mentioned.

### Investment policy

The Fund invests at least 80% of its assets in shares (equities) and equity-related securities of companies, which are biotechnology or biotechnology-related, of any size, including smaller capitalisation companies, in any country. The Fund may also invest in other assets including bonds (including convertible bonds), preference shares, cash and money market instruments. The investment manager may use derivatives (complex financial instruments) with the aim of making investment gains in line with the Fund's objective, to reduce risk or to manage the Fund more efficiently. The Fund is actively managed with reference to the NASDAQ Biotechnology Total Return Index, which is broadly representative of the companies in which it may invest, as this forms the basis of the Fund's performance target and the level above which performance fees may be charged (if applicable). The investment manager has discretion to choose investments for the Fund with weightings different to the index or not in the index, but at times the Fund may hold investments similar to the index.

### Investment strategy

The investment manager looks to identify innovative biotechnology companies addressing high unmet medical needs and trading at a significant discount to their intrinsic value. The team understands that success of drug development is binary in nature, creating wide disparities between winners and losers. The investment process leverages proprietary statistical models to analyse the probability of a company's success, focusing on products they believe can overcome the rigours of clinical development. Additional tools such as physician surveys, prescription models and scenario simulations attempt to more accurately predict commercial viability.

### Fund specific risks

When the Fund, or a share/unit class, seeks to mitigate exchange rate movements of a currency relative to the base currency (hedge), the hedging strategy itself may positively or negatively impact the value of the Fund due to differences in short-term interest rates between the currencies. The Fund could lose money if a counterparty with which the Fund trades becomes unwilling or unable to meet its obligations, or as a result of failure or delay in operational processes or the failure of a third party provider. Shares/Units can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result. Shares of small and mid-size companies can be more volatile than shares of larger companies, and at times it may be difficult to value or to sell shares at desired times and prices, increasing the risk of losses. If a Fund has a high exposure to a particular country or geographical region it carries a higher level of risk than a Fund which is more broadly diversified. The Fund is focused towards particular industries or investment themes and may be heavily impacted by factors such as changes in government regulation, increased price competition, technological advancements and other adverse events. The Fund may use derivatives to help achieve its investment objective. This can result in leverage (higher levels of debt), which can magnify an investment outcome. Gains or losses to the Fund may therefore be greater than the cost of the derivative. Derivatives also introduce other risks, in particular, that a derivative counterparty may not meet its contractual obligations. If the Fund holds assets in currencies other than the base currency of the Fund, or you invest in a share/unit class of a different currency to the Fund (unless hedged, i.e. mitigated by taking an offsetting position in a related security), the value of your investment may be impacted by changes in exchange rates. Securities within the Fund could become hard to value or to sell at a desired time and price, especially in extreme market conditions when asset prices may be falling, increasing the risk of investment losses. The Fund may incur a higher level of transaction costs as a result of investing in less actively traded or less developed markets compared to a fund that invests in more active/developed markets. These transaction costs are in addition to the Fund's Ongoing Charges.

**Janus Henderson**  
INVESTORS

FOR MORE INFORMATION PLEASE VISIT [JANUSHENDERSON.COM](https://www.janushenderson.com)

Source: Janus Henderson Investors, as at 31 December 2023, unless otherwise noted.

**ESG integration** is the practice of incorporating material environmental, social and governance (ESG) information or insights in a non-binding manner alongside traditional measures into the investment decision process to improve long term financial outcomes of portfolios. This product does not pursue a sustainable investment strategy or have a sustainable investment objective or otherwise take ESG factors into account in a binding manner. ESG related research is one of many factors considered within the investment process and in this material we seek to show why it is financially relevant.

**This document is intended solely for the use of professionals and is not for general public distribution. This is a marketing communication. Please refer to the prospectus of the UCITS and to the KID before making any final investment decisions. Any investment application will be made solely on the basis of the information contained in the Fund's prospectus (including all relevant covering documents), which will contain investment restrictions. This document is intended as a summary only and potential investors must read the Fund's prospectus and key information document before investing. A copy of the Fund's prospectus and key information document can be obtained from Janus Henderson Investors UK Limited in its capacity as Investment Manager and Distributor. For sustainability related aspects please access [Janushenderson.com](https://www.janushenderson.com). We may record telephone calls for our mutual protection, to improve customer service and for regulatory record keeping purposes. Past performance does not predict future returns. The performance data does not take into account the commissions and costs incurred on the issue and redemption of units. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested. Tax assumptions and reliefs depend upon an investor's particular circumstances and may change if those circumstances or the law change. If you invest through a third party provider you are advised to consult them directly as charges, performance and terms and conditions may differ materially. The securities included in this document are not registered in the Foreign Securities Registry of the Superintendencia de Valores y Seguros for public offering and, therefore, the use of this document is only**

for general information purposes. Nothing in this document is intended to or should be construed as advice. This document is not a recommendation to sell or purchase any investment. It does not form part of any contract for the sale or purchase of any investment. The Fund is a recognised collective investment scheme for the purpose of promotion into the United Kingdom. Potential investors in the United Kingdom are advised that all, or most, of the protections afforded by the United Kingdom regulatory system will not apply to an investment in the Fund and that compensation will not be available under the United Kingdom Financial Services Compensation Scheme. With effect from 1 January 2023, the Key Investor Information document (KIID) changed to the Key Information Document (KID), except in the UK where investors should continue to refer to the KIID. The Janus Henderson Horizon Fund (the "Fund") is a Luxembourg SICAV incorporated on 30 May 1985, managed by Janus Henderson Investors Europe S.A. Issued by Janus Henderson Investors. Janus Henderson Investors is the name under which investment products and services are provided by Janus Henderson Investors International Limited (reg no. 3594615), Janus Henderson Investors UK Limited (reg. no. 906355), Janus Henderson Fund Management UK Limited (reg. no. 2678531), (each registered in England and Wales at 201 Bishopsgate, London EC2M 3AE and regulated by the Financial Conduct Authority) and Janus Henderson Investors Europe S.A. (reg no. B22848 at 2 Rue de Bitbourg, L-1273, Luxembourg and regulated by the Commission de Surveillance du Secteur Financier). Copies of the Fund's Prospectus, Key Information Document, Articles of Incorporation, annual and semi-annual reports are available in English and other local languages as required from [www.janushenderson.com](http://www.janushenderson.com). These documents can also be obtained free of charge from the Registered Office of the Company at 2 Rue de Bitbourg, L-1273, Luxembourg. They can also be obtained free of charge from the local Facilities Agents and the Swiss representative and paying agent. Janus Henderson Investors Europe S.A. ("JHIESA"), 2 rue de Bitbourg, L-1273 Luxembourg, is the Facilities Agent in Austria, Belgium Germany, Ireland, Malta, Portugal, Sweden and Liechtenstein. JHIESA is also the Facilities Agent for France (Sub – TA is CACEIS). FE fundinfo (Luxembourg) S.à.r.l., 6 Boulevard des Lumières, Belvaux, 4369 Luxembourg, is the Facilities Agent in Denmark, Finland, Iceland, Netherlands, Norway, Poland and Greece. State Street Bank International GmbH – Succursale Italia, Società Generale Securities Services S.p.A (SGSS S.p.A), Allfunds Bank S.A.U filiale di Milano, Caceis Bank Italy Branch, and Banca Sella Holding S.p.A. are the Sub Transfer Agents for Italy. Allfunds Bank S.A., Estafeta 6, La Moraleja, Complejo Plaza de la Fuente, Alcobendas 28109, Madrid, Spain is the Facilities Agent in Spain (Janus Henderson Horizon Fund is registered with the CNMV under number 353). The Extract Prospectus, the key information documents, the Company's Articles as well as the annual and semi-annual reports may be obtained free of charge from the Swiss Representative. The Swiss Representative is FIRST INDEPENDENT FUND SERVICES LTD., Feldeggstrasse 12, CH-8008 Zurich. The Paying Agent in Switzerland is Banque Cantonale de Genève, 17, quai de l'Ile, CH-1204 Geneva. In respect of the units offered in Switzerland, the place of performance is the registered office of the representative. The place of jurisdiction is at the registered office of the representative or at the registered office or place of residence of the investor. The Hong Kong Representative is Janus Henderson Investors Hong Kong Limited of Suites 706-707, Chater House, 8 Connaught Road Central, Central, Hong Kong. Janus Henderson Investors (Singapore) Limited (Company Registration No. 199700782N), whose principal place of business is at 138, Market Street #34-03/04, CapitaGreen, Singapore 048946, Singapore (Tel: 65 6813 1000). The summary of Investors Rights is available in English from <https://www.janushenderson.com/summary-of-investors-rights-english>. Janus Henderson Investors Europe S.A. may decide to terminate the marketing arrangements of this Collective Investment Scheme in accordance with the appropriate regulation. Janus Henderson is a trademark of Janus Henderson Group plc or one of its subsidiaries. © Janus Henderson Group plc. D10003